Skip to content

Study · Randomized controlled trial · 2009

4 results

Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.

Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, Forsyth S, Reczko K, Johansson U, Fohlin H, Valentini M, Sainsbury R

Journal of the National Cancer Institute24 Feb 2009Cited by 37 (Europe PMC)

PMID19244174 (opens in a new tab)PMCIDPMC2650713 (opens in a new tab)DOI10.1093/jnci/djn498 (opens in a new tab)PepBankPUB-19244174
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women without tamoxifen, goserelin reduced events by 13.9 per 100 at 15 years (95% CI = 17.5 to 19.4).

    In plain wordsIn premenopausal breast cancer patients without tamoxifen, goserelin reduced events compared with no goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseEvents at 15 years without tamoxifen
    Study

    n: not reported in source

    Comparator
    No goserelin, without tamoxifen
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 4 weeks · injection · 2 yearsAs given in this study (human).

    Measurements

    Fewer events per 100 women
    13.9 events per 100 women
    goserelin vs no goserelin, no tamoxifen, 15 years
    95% CI as printed in source (fewer events)
    17.5 to 19.4 events per 100 women
    goserelin vs no goserelin, no tamoxifen, 15 years

    Source sentences

    Summary
    Fifteen years after the initiation of treatment, for every 100 women not given tamoxifen, there were 13.9 (95% confidence interval [CI] = 17.5 to 19.4) fewer events among those who were treated with goserelin compared with those who were not treated with goserelin.
    2 context sentences
    Summary · context
    We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years.
    Summary · context
    Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women who took tamoxifen, goserelin was associated with 2.8 fewer events per 100 women at 15 years (95% CI = 7.7 fewer to 2.0 more); the authors describe a marginal potential benefit.

    In plain wordsIn premenopausal breast cancer patients taking tamoxifen, adding goserelin was linked to fewer events, which the authors called a marginal potential benefit.

    Peptide
    Goserelin
    Outcome
    DecreaseEvents at 15 years with tamoxifen
    Study

    n: not reported in source

    Comparator
    Tamoxifen without goserelin
    Outcome group
    Tumor growth · Cancer
    Studied dose
    3.6 mg every 4 weeks · injection · 2 yearsAs given in this study (human).

    Measurements

    Fewer events per 100 women
    2.8 events per 100 women
    goserelin vs no goserelin, with tamoxifen, 15 years
    95% CI (fewer events; negative = more events)
    −2 to 7.7 events per 100 women
    goserelin vs no goserelin, with tamoxifen, 15 years

    Source sentences

    Summary
    However, among women who did take tamoxifen, there were 2.8 fewer events (95% CI = 7.7 fewer to 2.0 more) per 100 women treated with goserelin compared with those not treated with goserelin.
    2 context sentences
    Summary · context
    We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years.
    Summary · context
    Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women taking tamoxifen, goserelin yielded 2.6 fewer breast cancer deaths per 100 at 15 years (95% CI = 6.6 fewer to 2.1 more), without statistical significance.

    In plain wordsIn premenopausal breast cancer patients taking tamoxifen, adding goserelin did not significantly reduce breast cancer deaths.

    Peptide
    Goserelin
    Outcome
    No significant changeBreast cancer deaths at 15 years with tamoxifen
    Study

    n: not reported in source

    Comparator
    Tamoxifen without goserelin
    Outcome group
    Mortality · Cancer
    Studied dose
    3.6 mg every 4 weeks · injection · 2 yearsAs given in this study (human).

    Measurements

    Fewer breast cancer deaths per 100 women
    2.6 deaths per 100 women
    goserelin, with tamoxifen, 15 years
    95% CI (fewer deaths; negative = more deaths)
    −2.1 to 6.6 deaths per 100 women
    goserelin, with tamoxifen, 15 years

    Source sentences

    Summary
    The risk of dying from breast cancer was also reduced at 15 years: For every 100 women given goserelin, the number of breast cancer deaths was lower by 2.6 (95% CI = 6.6 fewer to 2.1 more) and 8.5 (95% CI = 2.2 to 13.7) in those who did and did not take tamoxifen, respectively, although in the forme…
    2 context sentences
    Summary · context
    We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years.
    Summary · context
    Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women without tamoxifen, goserelin reduced breast cancer deaths by 8.5 per 100 at 15 years (95% CI = 2.2 to 13.7).

    In plain wordsIn premenopausal breast cancer patients without tamoxifen, goserelin reduced breast cancer deaths compared with no goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseBreast cancer deaths at 15 years without tamoxifen
    Study

    n: not reported in source

    Comparator
    No goserelin, without tamoxifen
    Outcome group
    Mortality · Cancer
    Studied dose
    3.6 mg every 4 weeks · injection · 2 yearsAs given in this study (human).

    Measurements

    Fewer breast cancer deaths per 100 women
    8.5 deaths per 100 women
    goserelin, without tamoxifen, 15 years
    95% CI (fewer deaths)
    2.2 to 13.7 deaths per 100 women
    goserelin, without tamoxifen, 15 years

    Source sentences

    Summary
    The risk of dying from breast cancer was also reduced at 15 years: For every 100 women given goserelin, the number of breast cancer deaths was lower by 2.6 (95% CI = 6.6 fewer to 2.1 more) and 8.5 (95% CI = 2.2 to 13.7) in those who did and did not take tamoxifen, respectively, although in the forme…
    2 context sentences
    Summary · context
    We conducted long-term follow-up (median 12 years) of 2706 women in the Zoladex In Premenopausal Patients (ZIPP), which evaluated the LHRH agonist goserelin (3.6 mg injection every 4 weeks) and tamoxifen (20 or 40 mg daily), given for 2 years.
    Summary · context
    Women were randomly assigned to receive each therapy alone, both, or neither, after primary therapy (surgery with or without radiotherapy/chemotherapy).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.